- Home
- News & Events
- In the News
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
AI’s transformative role in drug discovery and development
In the Irish Times Life Sciences and Stem supplement, ICON’s CIO Tom O’Leary discussed AI is transforming drug development across a range of specific use cases, from discovery to clinical trials and post-marketing.
-
Girls see gender inequality as biggest barrier to pursuing Stem careers
Rose Kidd, President, Operations Delivery, provides an overview on how ICON is working to meet its gender balance ambitions in the Irish Times Life Sciences and Stem supplement.
-
To advance in life sciences we must be more ambitious and prioritise public investment in research
In this article from the Irish Times Life Sciences and Stem supplement, Barry Balfe, President, ICON Pharma Solutions, outlines his views on how Ireland’s life sciences sector can continue to grow and attract investment.
-
The move to greener clinical development
Sustainability requires a layered approach that balances operational feasibility and with greener practices. Sean Morgan, Director of Clinical Supplies Management, discusses how ICON is tackling issues like kit waste, carbon emissions and ethical supply chains.
-
To be precise: How oncology therapies can stand out in a diverse, uncertain landscape
Targeted product profiles and biomarkers for patient screening are essential elements of success for oncology treatment developers, according to our recent survey. This article explores why both prove challenging for drug developers.
-
Half of pharma and biotech companies using AI and big data
This news piece from Clinical Trials Arena provides an overview of the findings of ICON’s recent Digital Disruption survey, which found sentiment towards artificial intelligence and digital tools in the clinical research sector is positive.
-
Outcome measures: Patients beyond endpoints
The evolving regulatory requirement to put patients at the centre of the drug development process – patient-centric from end to end – means pharmaceutical sponsors must design clinical trials with patient-centred outcomes in mind.
-
Curated and customised outsourcing
As the outsourcing market evolves, pharmaceutical businesses are reassessing their strategies to better insulate themselves against the pressure of compounding macroeconomic constraints, including a looming patent cliff, rising costs and developmental risks.
-
Women Mean Business (WMB) Businesswoman Award 2024
Following her receipt of the WMB Businesswoman Award 2024, Rose Kidd, President, Operations Delivery is interviewed by Women Mean Business on her role, the opportunities for the life sciences industry and her views on how we can support more women to progress STEM careers.
-
Striking the right balance between transparency and privacy in clinical trial data sharing
In this article, our experts explore how to strike the right balance between adequately anonymising clinical trial data to protect participant privacy and company assets, while still preserving its value for research purposes (see page 16).